Acrux (ACR)

Shares / Stock Code

ACR

Stock Exchange / Sharemarket

ax

Acrux (ACR) is a pooled development fund which invests primarily in pharmaceutical businesses developing new products involving the delivery of pharmaceuticals via the skin. ACR was listed on the Australian Stock Exchange (ASX) on 29 September, 2004. Acrux is engaged in the pharmaceutical research and development industry in the field of dynamic drug delivery, the development and commercialization of healthcare products. Acrux's first product, "EvaMist", has been approved by United States Food and Drug Administration (FDA). Other products by the company in the pipeline include: Testosterone MDTS, Nestorone MDTS and Fentanyl MDTS.

The company owns the proprietary transdermal drug delivery technology which allows certain drugs to be given cleanly, safely and reliably through the skin. Acrux's transdermal drug deliver system is less messy, standarised dosages and continuous blood levels are its benefits of use. The technology is ahead of competitors because of its ability to create an invisible reservoir of active drug just under the surface layer of the skin. This prevents the drug from being inadvertently washed off or transferred to another person through skin contact. The reservoir also ensures gradual seepage into the bloodstream with the desirable effect that constant blood levels can be maintained.

Acrux Company History

Acrux was first formed in 1998 after the development of the transdermal drug technology at Monash University. ACR had raised $26M in three rounds of private funding before public listing and also received $4M of grant funding. These funds were used to build a management team for the company and push seven compounds into the clinical trials phase.